National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ocrelizumab (Ocrevus®) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

 

NCPE Assessment Process Complete
Rapid review received 29/11/2017
Rapid review completed 14/12/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 17/01/2018
Pre-submission consultation with Applicant 20/02/2018
Submission received from Applicant 16/03/2018
Preliminary review sent to Applicant 25/07/2018
NCPE assessment re-commenced 13/08/2018
Factual accuracy sent to applicant 13/08/2018
NCPE assessment re-commenced 16/08/2018
NCPE assessment completed 29/08/2018
NCPE assessment outcome
The NCPE recommends that ocrelizumab (Ocrevus®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Summary